Ellevest Inc’s Relay Therapeutics RLAY Stock Holding History

Ellevest Inc’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-19	Closed	–	–	1816
2022 Q2	$0	Buy	19 +8	+73%	+$171	﹤0.01%	1639
2022 Q1	$0	Buy	+11	New	+$267	﹤0.01%	1602

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ellevest Inc's RLAY Position: Q3 2022 in Review

Ellevest Inc sold out of Relay Therapeutics (RLAY) in Q3 2022, closing a stake of 19 shares.

Ellevest Inc first reported a position in RLAY in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 161 funds tracked by Wall St. Rank hold RLAY as of Q3 2022.

Ellevest Inc reported no remaining Relay Therapeutics position as of Q3 2022 after selling out during the quarter.
Ellevest Inc sold 19 Relay Therapeutics shares in Q3 2022.
Ellevest Inc first reported a position in Relay Therapeutics in Q1 2022 and held it in 2 quarters.
Ellevest Inc's Relay Therapeutics position peaked at $0 in Q2 2022.
161 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2022.

Based on Ellevest Inc's 13F filing for Q3 2022, filed 2 Nov 2022.